We Impart Health to Life Provide end-to-end pharmaceuticals solutions Centaur Pharmaceuticals Pvt. Ltd. We Impart Health to Life

We Impart Health to Life Business Spread (Sales)Geographical Spread (Sales) Corporate API Formulations Domestic Sales International Sales 31% 69% 22% 78%

We Impart Health to Life Established 1978 Rank 51 - IMS-ORG (India) Rank 45 - Rx audit- CMARC Exports to 95 countries Competencies across the pharmaceutical value chain Corporate ORG Nov11/CMARC Jul-Oct11/AWACS Dec11

We Impart Health to Life Our assets Centaurians API 110 Centaur House 230 Formulations Facilities 450 Sales Force 1150 CRO 60

We Impart Health to Life Contract Manufacturing, Pune We Impart Health to Life  Fully scalable formulations facility 25,000 square metres  Approved by USFDA, UK MHRA, TGA, Health Canada  Annual capacity 3 billion tablets & 600 million capsules  Formulations and Analytical R&D  On the anvil, Ophthalmics–12 million units pa

We Impart Health to Life WHO-GMP Approved Formulations Facilities- Goa PlantDepartmentCapacityUnitBuilt Up Area Sq M Plant ILiquids25Million L 3577 Tablets & Capsules600Million Vials (Sterile)10Million L Plant II OintmentsTopical 0.75 Sterile 0.2 Tonnes1280

We Impart Health to Life API, Ambernath India's largest Psychotropic API player, introduced 28 API in India USFDA / AFSSAPS approved Proficiency- Conceptualisation to Commercialisation Clientele: Big Pharma and generic majors

We Impart Health to Life  Exports to Asia, Americas, Africa  India- 50 million+ Rx annually  Brand leader in 6 therapy segments  1145 Sales force, 10,000 Drs and 10,000 pharmacies daily Formulations Marketing 1 Rx / Second 33Mn Rx / Year

We Impart Health to Life Total Sales Force 1145 TeamMRManagerTotalSales Share % Focus Specialities Samruddhi ENT, Chest, Physicians Shasvatam Paediatricians, Dermatologists Praggya Ophthalmologists, ENT Sankalp Cardiologists, Diabetologists, Nephrologists Centaur All teams cover GP

We Impart Health to Life Contract Research Fully integrated set-up- BA / BE / Clinical trials (Phase II/III) International standard CRO -10,000 sq.ft. 42 bed CPU, fully-equipped ICU Formulations & API development

We Impart Health to Life PartnerCountryMoleculeIndicationStatus JapanSorivudine Topical antiviral for Herpes Zoster Development & distribution rights for India++ Centaur to conduct PII/PIII trials, launch 2014 Japan Timolol LAGlaucoma Launched 2011 BromfenacNSAID Launch 2012 Germany DPOCL (Diperoxochloric Acid) Diabetic Foot Ulcer solution NCE, development rights Phase II successful Phase III WIP Launch by 2013 Strategic Alliances Strategy- Harness CRO, API & marketing proficiencies

We Impart Health to Life Strategic Alliances APIContract Manufacturing Contract Research EUSynthon, EGIS, Stada, NTIM, Mylan, Pfizer, Mayoli Spindler GSK, Blue Fish NRIM, Zanza, Wockhardt, Aurobindo, Bluemont Wessex, Kirka Orion,Hennig- Arzneimittel, AmericasSepracor, Pharmascience, Actavis, Lab Teuto, Ratiopharm, Apotex, Caraco, Mylan, Sandoz Allergan, Euro Pharma, STI, Ingenus, IPG AfricaDelta Pharma, Al-andalous, Cooper Moroc IndiaWyeth, Sun Pharma, Intas, Zydus, Alcon, Nicholas Sanofi-Aventis, Novartis Inventia Rest of APac Rodan, IndusPharma, Sami Pharma, Wilshire Labs, ACME, Healthcare, General, Delta, Sandoz Generic Partners, Thinz

We Impart Health to Life API Contract Manufacturing Contract Research Formulations USFDA/EU API proficiencies BA/BE studies Clinical trials R&D Pan India 1145 Sales Force 50,000,000 Rx 250,000 Drs and pharmacies / month USFDA/ UKMHRA/ TGA World scale capacity Why Centaur

We Impart Health to Life Formulations API Contract Research Contract Manufacturing Future

We Impart Health to Life Centaur Pharmaceuticals Pvt. Ltd. Centaur House, Vakola, Santacruz (E), Mumbai INDIA Tel. : Fax : / 112 Website: BusinessE mail / WebsiteWebsite API & Formulations Contract Manufacturing Contract Research Contact